ENTRY       D10454                      Drug
NAME        Cantuzumab ravtansine (USAN/INN)
FORMULA     C6570H10130N1726O2018S44(C42H59ClN3O11S2)n
SEQUENCE    (Heavy chain)
            XVQLVQSGAE VKKPGETVKI SCKASDYTFT YYGMNWVKQA PGQGLKWMGW IDTTTGEPTY
            AQKFQGRIAF SLETSASTAY LQIKSLKSED TATYFCARRG PYNWYFDVWG QGTTVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            DIVMTQSPLS VPVTPGEPVS ISCRSSKSLL HSNGNTYLYW FLQRPGQSPQ LLIYRMSNLV
            SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCLQHLEYP FTFGPGTKLE LKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H146-H202, H222-L219 H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'96, H'146-H'202, H'222-L'219, H'263-H'323, H'369-H'427, L23-L93, L139-L'199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
EFFICACY    Antineoplastic
  TYPE      Antibody-drug conjugate
TARGET      CA242
            TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  PATHWAY   hsa04540(10381+10382+10383+203068+347688+347733+7280+81027+84617)  Gap junction
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                TUBB
                 D10454  Cantuzumab ravtansine (USAN/INN)
DBLINKS     CAS: 868747-45-9
            PubChem: 172232547
///
